Seiwerth, S., Milavi?, M., Vukojevi?, J., Gojkovi?, S., Krezi?, I., Batelja Vuleti?, L., Horvat Pavlov, K., Petrovi?, A., Sikiric, S., Vrane, H., Prtoric, A., iek, H., ?urain, T., Dobri?, I., Stareini?, M., trbe, S., Kneevi?, M., ola, M., Kokot, A., & Sever, M
Wegovy is a GLP-1 receptor agonist licensed for chronic weight management in adults with obesity or overweight with comorbidities, whilst lisdexamfetamine is a central nervous system stimulant indicated for attention deficit hyperactivity disorder (ADHD)
Reporting Adverse Events Seek Immediate Medical Attention If you experience severe adverse events such as difficulty breathing, chest pain, significant swelling, or sudden confusion, seek emergency care
Elimination Semaglutide elimination half-life is approximately one week with an absolute clearance of approximately 0.04 L/hour in patients with type 2 diabetes
Ethics declarations Conflict of interest The authors declare that there are no competing conflict of interest